Japanese Bio Venture Company Transparent And Toyo Gosei Jointly Market Drug Discovery Screening Kit
This article was originally published in PharmAsia News
Executive Summary
Chiba prefecture-based Transparent, a biology venture company funded by Tokyo University of Science and Toyo Gosei, a pharmaceutical material maker announced May 15 that they have jointly developed and marketed Cell-able, a drug discovery screening kit to culture liver cells in a close to in-vivo environment. Cell-able can be used to conduct 96 tests on a single plate which is eight times greater than current methods. Transparent hopes to reach ¥100 million in sales this year, and will launch Cell-able overseas next year and hopes to reach ¥3 billion in sales by 2012. (Click here for more - Japanese language
You may also be interested in...
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.
QUOTED. 22 January 2021. Neil Moat.
The Centers for Medicare and Medicaid Services has agreed to provide national Medicare coverage for mitral valve transcatheter edge-to-edge repair under a new coverage with evidence development policy. See what Neil Moat, chief medical officer for Abbott’s structural heart business, said about it here.
ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC
South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.
Need a specific report? 1000+ reports available
Buy Reports